The role of phosphatidylethanolamine methylation in the secretion of very low density lipoproteins by cultured rat hepatocytes: rapid inhibition of phosphatidylethanolamine methylation by bezafibrate increases the density of apolipoprotein B48-containing lipoproteins.
The role of phosphatidylcholine (PC) synthesis via the phosphatidylethanolamine (PE) methylation pathway in the secretion of very low density lipoproteins (VLDL) by cultured rat hepatocytes has been investigated by determining the effects of inhibitors. We have shown that bezafibrate and clofibric acid, known hypolipidemic agents, are potent inhibitors of PE methylation (see accompanying paper by Nishimaki-Mogami et al. (1996) Biochim. Biophys. Acta 1304). In hepatocytes incubated with ethanolamine, which maintained cellular PE levels and PE methylation activity, bezafibrate (200 microM) decreased the secretion of triacylglycerol (TG), PC, apolipoproteins B48, and E in VLDL by 50-75%. In contrast, bezafibrate at this concentration had marginal effect on VLDL secretion (83-115% of control) by hepatocytes that had been cultured in the absence of ethanolamine. In these cells PE levels and PE methylation activity had decreased by approx. 40%. VLDL secretion was decreased at concentrations similar to those required to inhibit PE methylation, and was accompanied by an increase in cellular TG levels. The same ethanolamine-dependent effects were produced by clofibric acid and also by 3-deazaadenosine (DZA), an inhibitor of cellular methylation reactions. These results indicate that PC synthesis via the PE methylation pathway plays a significant role in VLDL secretion in rat hepatocytes if the pathway is maintained at levels comparable to those in vivo. The reductions of PE methylation by bezafibrate and DZA did not affect the total amount of apolipoprotein B48 secreted into the medium. The decrease in apolipoprotein B48 in VLDL caused by bezafibrate was accompanied by an increase in apolipoprotein B48 in the HDL density range. In contrast, the amount of apolipoprotein B100 in VLDL and density determined by sequential flotation were unaffected. These findings indicate that rapid reduction of PC synthesis via PE methylation does not affect the secretion of apolipoprotein B48- or B100-containing lipoprotein particles, but does impair the lipidation of particles containing apolipoprotein B48, but not apolipoprotein B100.
Nishimaki-Mogami
T
T
National Institute of Health Sciences, Tokyo, Japan. mogami@nihs.go.jp
Suzuki
K
K
Takahashi
A
A
D000818:Animals; D053283:Apolipoprotein B-48; D001055:Apolipoproteins B / Q000032:analysis*; D001629:Bezafibrate / Q000494:pharmacology*; D002478:Cells, Cultured; D002995:Clofibric Acid / Q000494:pharmacology; D004305:Dose-Response Relationship, Drug; D004791:Enzyme Inhibitors / Q000494:pharmacology*; D019856:Ethanolamine; D004983:Ethanolamines / Q000494:pharmacology; D005260:Female; D007930:Leucine / Q000378:metabolism; D008079:Lipoproteins, VLDL / Q000378:metabolism*; D008099:Liver / Q000166:cytology / Q000378:metabolism*; D008745:Methylation / Q000187:drug effects; D008780:Methyltransferases / Q000032:analysis; D010713:Phosphatidylcholines / Q000378:metabolism; D050918:Phosphatidylethanolamine N-Methyltransferase; D010714:Phosphatidylethanolamines / Q000378:metabolism*; D051381:Rats; D017208:Rats, Wistar; D013046:Specific Gravity; D014372:Tubercidin / Q000494:pharmacology
D053283:Apolipoprotein B-48; D001055:Apolipoproteins B; D004791:Enzyme Inhibitors; D004983:Ethanolamines; D008079:Lipoproteins, VLDL; D010713:Phosphatidylcholines; D010714:Phosphatidylethanolamines; C018258:3-deazaadenosine; D002995:Clofibric Acid; D019856:Ethanolamine; D008780:Methyltransferases; D050918:Phosphatidylethanolamine N-Methyltransferase; D007930:Leucine; D014372:Tubercidin; D001629:Bezafibrate